CONMED (NYSE: CNMD) grants RSUs and stock options to EVP

Rhea-AI Filing Summary

SHAGORY PETER K reported acquisition or exercise transactions in this Form 4 filing.

CONMED Corp granted equity awards to executive Peter K. Shagory, EVP, Strategy & Corporate Development. He received 9,282 RSUs (Restricted Stock Units), each representing one future share of common stock, under the company’s 2025 Long-Term Incentive Plan.

The RSUs generally vest over three years, with 33% vesting after one year, another 33% after two years, and 34% after three years from the March 2, 2026 grant date. He was also granted 10,999 stock options under the same plan, which generally vest in equal 25% installments over four years, starting one year after the grant date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider SHAGORY PETER K

Role EVP, STRAT & CORP DEVT

Type	Security	Shares	Price	Value
Grant/Award	RSUs (Restricted Stock Units)	9,282	$0.00	--
Grant/Award	Options To Purchase Common Stock	10,999	$0.00	--

Holdings After Transaction: RSUs (Restricted Stock Units) — 9,282 shares (Direct); Options To Purchase Common Stock — 10,999 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year. The stock options were granted under CONMED Corporation Corporation's 2025 Long-Term Incentive Plan, with the stock options generally vesting in equal amounts over a four-year period with the first 25% of the stock options vesting one year after the grant date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SHAGORY PETER K

(Last) (First) (Middle)

C/O CONMED CORPORATION

11311 CONCEPT BOULEVARD

(Street)

LARGO FL 33773

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, STRAT & CORP DEVT

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
RSUs (Restricted Stock Units)	$0	03/02/2026		A		9,282		(1)	03/02/2036	Common Stock	9,282	$0	9,282	D
Options To Purchase Common Stock	$45.79	03/02/2026		A		10,999		(2)	03/02/2036	Common Stock	10,999	$0	10,999	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.

2. The stock options were granted under CONMED Corporation Corporation's 2025 Long-Term Incentive Plan, with the stock options generally vesting in equal amounts over a four-year period with the first 25% of the stock options vesting one year after the grant date.

	/s/ Thomas Fistek for Peter K. Shagory by Power of Attorney	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CONMED (CNMD) report for Peter K. Shagory?

CONMED reported equity award grants to EVP Peter K. Shagory. He received 9,282 RSUs and 10,999 stock options under the 2025 Long-Term Incentive Plan, reflecting routine executive compensation rather than open-market share purchases or sales.

How many RSUs were granted to the CONMED (CNMD) executive in this Form 4?

Peter K. Shagory was granted 9,282 RSUs. Each RSU represents a contingent right to receive one share of CONMED common stock, subject to the company’s 2025 Long-Term Incentive Plan terms and the three-year vesting schedule described in the filing footnote.

What is the vesting schedule for CONMED (CNMD) RSUs granted to Peter K. Shagory?

The 9,282 RSUs generally vest over three years. About 33% vest one year after the grant date, another 33% in the second year, and the remaining 34% in the third year, assuming continued compliance with the plan’s terms and conditions.

How many stock options did CONMED (CNMD) grant to Peter K. Shagory?

CONMED granted 10,999 stock options to Peter K. Shagory. These options were issued under the 2025 Long-Term Incentive Plan and are reported at a price of $0.00 per option, reflecting a grant, not an open-market transaction or cash purchase.

What is the vesting schedule for CONMED (CNMD) stock options in this Form 4?

The 10,999 stock options generally vest in equal 25% installments over four years. The first 25% vests one year after the grant date, with additional 25% portions vesting in each of the following three years, subject to plan conditions.

Are the CONMED (CNMD) RSU and option grants on this Form 4 open-market trades?

No, these are equity awards, not market trades. The filing shows grants of RSUs and stock options under CONMED’s 2025 Long-Term Incentive Plan, reflecting compensation awards rather than the executive buying or selling existing shares in the open market.